SnapShot: The hallmarks of cancer treatment.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 41997133.
- Also identified by DOI 10.1016/j.cell.2026.03.017.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Cancer therapy evolved from cytotoxic chemotherapy to targeted and immune treatments guided by molecular profiling. Early cytotoxic drugs, rooted in mustard-gas observations, remain effective but toxic. Targeted agents exploit oncogenic vulnerabilities yet commonly select resistant clones. Checkpoint inhibitors and engineered modalities (ADCs, BiTEs, CAR-T) yield responses but are limited by toxicity and adaptive antigen loss. Future treatment combinations will require targeting the evolution of resistance. To view this SnapShot, open or download the PDF.
Medical subject headings
- Neoplasms